SCM
CRDF icon

Soleus Capital Management’s Cardiff Oncology CRDF Stock Holding History

Soleus Capital Management’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-42,684
Closed -$395K – 67
2021
Q1 		$395K Sell
42,684
-14,225
-25% -$173K 0.07% 72
2020
Q4 		$1.02M Sell
56,909
-224,910
-80% -$3.95M 0.14% 52
2020
Q3 		$4M Buy
+281,819
New +$1.86M 2.12% 19

Other funds holding CRDF

EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Soleus Capital Management's CRDF Position: Q2 2021 in Review

Soleus Capital Management sold out of Cardiff Oncology (CRDF) in Q2 2021, closing a stake of 42,684 shares — an estimated $395K sold.

Soleus Capital Management first reported a position in CRDF in Q3 2020 and held it in 3 quarters. The position peaked at $4M in Q3 2020. 90 funds tracked by Wall St. Rank hold CRDF as of Q2 2021.

  • Soleus Capital Management reported no remaining Cardiff Oncology position as of Q2 2021 after selling out during the quarter.
  • Soleus Capital Management sold 42,684 Cardiff Oncology shares in Q2 2021, an estimated $395K.
  • Soleus Capital Management first reported a position in Cardiff Oncology in Q3 2020 and held it in 3 quarters.
  • Soleus Capital Management's Cardiff Oncology position peaked at $4M in Q3 2020.
  • 90 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2021.

Based on Soleus Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.